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Myocardial infarction as a thrombotic complication 
of essential thrombocythemia and polycythemia vera
Introduction
Essential thrombocythemia (ET) and polycythemia vera (PV) 
are listed by the World Health Organization as chronic Phila-
delphia chromosome-negative myeloproliferative neoplasms 
(MPNs); these are characterized by increased levels of hemo-
globin and red cell mass due to the proliferation of the erythroid 
lineage (PV) or the overproduction of circulating platelets in the 
periphery due to the excessive proliferation of megakaryocytes 
in the bone marrow (ET) (1–4). These patients are at a possible 
risk of the condition to progressing to myelofibrosis or/and acute 
myeloid leukemia. The reported 10-year risk of leukemic/fibrotic 
transformation is less than 1% in ET and 3%–10% in PV (4–6). In 
contrast, the incidence of thrombohemorrhagic complications, 
which are mostly responsible for the morbidity and mortality of 
ET/PV patients, is much higher, at an estimated 11%–39% (4–7). 
MPN-related hemostatic abnormalities and the pathogen-
esis of the thrombosis seen in ET or PV are currently highlighted 
topics. These conditions are complex and multifactorial, and be-
sides the quantitative changes in the platelets, erythrocytes, or 
leukocytes, it is strongly suggested that the qualitative changes 
in them may initiate and contribute to the circulatory complica-
tions (8, 9).
The currently used thrombosis risk stratification is based 
on only two risk factors and classifies the patients into low-risk 
(age <60 years, without a prior thrombotic event) and high-risk 
(age >60 years and/or with a prior thrombotic event) catego-
ries (4, 10). An increasing number of publications have recently 
promoted the rethinking of the thrombosis risk stratification of 
ET/PV patients from a clinical aspect (4–6, 11–21). The impact 
of additional molecular or clinical risk factors that improve the 
prediction of ET/PV-related thrombotic complications has been 
reported, including the Janus kinase 2 (JAK2) V617F mutation (in 
ET/PV) and calreticulin mutational status (in ET) or thrombocyto-
sis, leukocytosis, and atherosclerotic risk factors; however, no 
clear consensus has emerged (4–6, 13–25). 
Objective: Detailed analyses of clinical characteristics of myocardial infarction (MI) as an essential thrombocythemia (ET)- and polycythemia 
vera (PV)-related complication have been so far presented mostly as case reports. Therefore, the aim of this retrospective analysis was to evalu-
ate the main cardiological and hematological characteristics for better understanding myocardial complications in ET/PV.
Methods: A retrospective analysis was carried out involving 263 patients diagnosed with ET or PV (155/108) between 1998 and 2014. Fourteen 
patients suffered MI during the hematological follow-up. Their clinical characteristics were compared to 162 patients (97 ET and 65 PV patients) 
who did not exhibit any major thrombotic complications (MI, stroke/transient ischemic attack, and venous events) before or after hematological 
diagnosis of ET/PV.
Results: Fourteen MI events occurred among the 263 patients (5.3%). Vascular risk factors were found in 92.9% (13/14) of analyzed cases. In all, 
71.4% of the MI complications developed within 12 months after the diagnosis of ET/PV. The coronary angiography findings revealed ST-elevation 
MI in four cases and non-ST-elevation MI in 10. Significant stenosis of coronary arteries requiring percutaneous coronary intervention with a 
stent implantation was present in seven cases, while three had complex stenoses or previous grafts/stents. All of them had undergone coronary 
artery bypass graft operations.
Conclusion: The results of the present study suggest that early detection and consideration of individual management of vascular risk factors in 
ET/PV patients are also important. Furthermore, a better theoretic understanding of platelet activation and role of leukocytes in myeloprolifera-
tive neoplasm-related thrombosis could open new perspectives in thrombosis prediction and prevention. (Anatol J Cardiol 2016; 16: 000-000)
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Among the major thrombotic complications, arterial throm-
bosis is responsible for the great majority of thrombohemor-
rhagic complications, including ischemic stroke, myocardial in-
farction (MI), and peripheral arterial occlusion (5). The incidence 
of MI has been reported in large multicenter studies, but detailed 
analyses of the associations and clinical characteristics of MI 
as an MPN-related complication are presented mostly in case 
reports (7, 26–33). 
Our study aim was to add beneficial information that may 
contribute to the better understanding of myocardial infarction 
as a complication of ET/PV. The detailed aims of our retrospec-
tive analysis were to assess the incidence and the main car-
diological characteristics of MI (type of MI, coronary angiogra-
phy findings) as a severe MPN-related complication in a recent 
patient population and to compare their clinico-hematological 
characteristics (JAK V617F mutation, peripheral blood counts, 
vascular risk factors) with those of ET/PV patients who had 
never suffered from thrombotic complications [MI, stroke/tran-
sient ischemic attack (TIA), or venous complication events (deep 
venous thrombosis or pulmonary embolism thrombosis and ce-
rebral sinus and venous thrombosis)] neither before the hemato-
logical diagnosis nor during the hematological follow-up period. 
Methods
Patient population 
Between 1998 and 2014, 263 patients were diagnosed with 
ET/PV in our academic center (mean age: 56.9±15.5 years, range: 
19–91 years). Through the use of the medical data files, all the he-
matological and cardiological results on these patients were re-
viewed with the approval of the Regional and Institutional Human 
Medical Biological Research Ethics Committee. The study was 
conducted in full accordance with the Declaration of Helsinki.
The following inclusion and exclusion criteria were used. Pa-
tients were selected retrospectively from the myeloproliferative 
neoplasm database established for scientific research at the 2nd 
Department of Internal Medicine and Cardiology Centre. Patients 
diagnosed with ET/PV during 1998–2014 were enrolled the study. 
The thrombotic events before and after clinical diagnosis of ET/
PV were retrospectively collected for each patient, with focus on 
MI, ischemic stroke or TIA, and venous thrombotic events (such 
as deep venous thrombosis or pulmonary embolism thrombosis, 
and cerebral sinus and venous thrombosis). Patients who had 
MI during the hematological follow-up period were selected and 
compared with those of ET/PV patients who had never suffered 
from the aforementioned thrombotic complications—neither 
before the hematological diagnosis nor during/after the hema-
tological follow-up period. Patients who reported other inherited 
or acquired thrombophilia at the time of the hematological di-
agnosis (such as increased lipoprotein A level) were excluded 
from the study.
The hematology management strategy was based on risk-ori-
ented recommendations: anti-platelet therapy was administered 
to low-risk patients in certain cases (aged <60 years and without 
a prior history of thrombosis), while the high-risk patients (aged 
≥60 years, or/and with a prior thrombosis) received cytoreduc-
tive drugs (e.g., hydroxyurea) alone or in combination with anti-
platelet medication. Phlebotomy was recommended for low-risk 
PV patients and before the cytoreductive treatment in high-risk 
PV patients, in order to reach the target hematocrit level below 
0.45, respectively (10, 34). 
Laboratory analysis
Routine blood analysis with automated blood count equip-
ment was performed as part of the diagnostic protocol. DNA 
was isolated from EDTA-stabilized peripheral blood samples and 
screened for the JAK2 V617F mutation (35).
Statistical analysis 
Continuous variables are expressed as mean values ± stan-
dard deviation, and categorical variables are summarized as per-
centages. The unpaired t-test was used for comparing param-
eters of groups. A p value of <0.05 was considered statistically 
significant. All the analyses were performed with commercially 
available software (pl. Medcalc, Mariakerke, Belgium).
Results
During the hematological follow-up period, MI events were 
reported in 14 (5.3%) of the enrolled 263 patients (five males, 
mean age: 65.7 years, range: 38–80 years). Most of the MI (10/14, 
71.4%) complications appeared within 1 year after the hemato-
logical diagnosis of ET or PV. JAK V617F mutation positivity was 
also present in most of the cases (10/14, 71.4%). Vascular risk 
factors appeared in the majority of patients (13/14, 92.8%), and 
8/14 (57.1%) exhibited two or more vascular risk factors.
In eight ET patients who suffered from MI, a tendency 
could be demonstrated in the decrease of mean peripheral 
platelet count between the hematological diagnosis and the 
time of the MI events, whereas the mean hemoglobin, mean 
hematocrit, and mean red blood cell count remained basically 
unchanged. The mean white blood cell count increased mark-
edly (Table 1). 
In the six PV patients who suffered from MI, the mean plate-
let count, mean hemoglobin, mean hematocrit, and mean red 
blood cell count showed similar reduction tendencies between 
the time of hematological diagnosis and the time of the MI event, 
although the mean white blood cell count increased (Table 1). 
Data on the patients who did not exhibit thrombotic complica-
tions earlier during the follow-up period are also given in Table 
1. In both PV-AMI and ET-AMI groups, these aforementioned 
changes were not significant.
The mean hematocrit value was 44.8% and the mean hemo-
globin value was 13.8g/L in the cases of ET patients without any 
thrombotic events (before the hematological diagnosis and dur-
ing the follow-up hematological period). In the cases of PV pa-
tients without any thrombotic complications, the mean hemato-
crit value was 50.9% and the mean hemoglobin value was 17.3g/L.
Following summarization of data of ET/PV patients with 
thrombotic events in order to compare them with that of ET/PV 
patients without thrombotic events, no significant differences 
was found between the groups (Table 1). 
STEMI was diagnosed in four cases and NSTEMI in 10. De-
tailed angiographic results are presented in Table 2. Significant 
stenosis of coronary arteries requiring percutaneous coronary 
intervention with a stent implantation was present in seven cas-
es, while three had complex stenoses or previous grafts/stents. 
All of them had undergone coronary artery bypass graft opera-
tions. Recanalization proved to be unsuccessful in one case. 
Coronary angiography showed only normal epicardial coronary 
artery arteries in one case, non-significant stenoses in one, and 
distal occlusion in one. 
Discussion
The reported incidence of ET-related and PV-related MI com-
plications was found to be 9.4% and 11.4%, respectively (31). 
The present cohort exhibited a lower incidence of MI both in ET 
(5.2%) and in PV (5.6%).
The JAK2 V617F mutation, an acquired gain-of-function muta-
tion in exon 14 of the JAK2 gene, is present in some 50%–60% of ET 
patients and in almost all patients with PV (5, 14, 36). JAK2 mutation 
analysis has become a diagnostic criterion for ET/PV, but despite 
the association between the mutation and an enhanced tendency 
to major thrombotic complications, its prognostic value is limited 
(5, 14, 37). Our current analysis, focusing on MI complications, re-
vealed a JAK2 V617F mutation-positive status in majority of the cas-
es (10/14, 71.4%) and in all patients who suffered from other major 
arterial thrombotic complications, such as in ET-related stroke (38).
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Table 1. Comparison of clinical characteristics of patients without prior/follow-up thrombotic complications and patients who suffered MI 
during the follow-up period of ET/PV
Characteristics ET/PV patients without  ET patients with MI PV patients with MI 
  prior/follow-up (n=8) (n=6) 
  thrombotic complications 
  (n=162)
Males, (%) 61, (38) 4, (50) 1, (17)
Age at diagnosis, mean years, range 57±16, 20–89 63±14, 38–80 70±5, 64–76
Hepatomegaly, n, (%) 30, (19)  1, (13) 2, (33)
Splenomegaly, n, (%) 30, (19)  0, (0) 1, (17)
Hepatosplenomegaly, n, (%) 15, (9) 3, (38) 1, (17)
Platelet counts
 Mean platelet count at ET/PV diagnosis, G/L 577±340  651±181 553±325
 Mean platelet count at the time of the MI event, G/L – 571±161 417±182
Hemoglobin
 Mean hemoglobin at ET/PV diagnosis, g/L 153±27  132±29 169±37
 Mean hemoglobin at the time of the MI event, g/L – 133± 27 161±44
Hematocrit
 Mean hematocrit at ET/PV diagnosis, % 47±28 40±9 53±9
 Mean hematocrit at the time of the MI event, % – 40±7 50±8
Red blood cell count
 Mean red blood cell count at ET/PV diagnosis, T/L 5.1±1.1  4.6±1.3 6.5±0.6
 Mean red blood cell count at the time of the MI event, T/L –  4.7±0.9 6.1±0.4
White blood cell count
 Mean white blood cell count at ET/PV diagnosis, G/L 10.8±12.5 11.3±2.6 11.3±5.7
 Mean white blood cell count at the time of the MI event, G/L – 17.8±9.9 13.5±5.8
Mutation
 JAK2 V617F-positive cases, n, (%) 126, (78)   5, (62.5) 5, (83)
Risk categories
 Low-risk cases 39, (24) 3, (37.5) 0, (0)
 High-risk cases  123,(76) 5, (62.5) 6, (100)
ET - essential thrombocythemia; MI - myocardial infarction; PV - polycythemia vera
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At least one vascular risk factors displayed by most of the 
patients with MI complications (13/14, 92.9%), and 8/14 (57.1%) 
of them exhibited two or more vascular risk factors, such as 
smoking, hypertension, diabetes, and hyperlipidemia. This draws 
attention to the controversial topic of whether cardiovascular 
risk factors have an important role in the thrombosis risk-guided 
management and stratification of MPNs (17, 39). 
Our analyses revealed a decrease in elevated platelet 
count between the time of hematological diagnosis of ET and 
the time of cardiological thrombotic complications, as well as 
corresponding decreases in the mean platelet, hemoglobin, 
hematocrit, and red blood cell count in PV. We presume that 
the applied hematological therapy is responsible for these 
changes. However, the results indirectly support the idea 
that besides the quantitative changes in the platelets and 
erythrocytes, qualitative changes in them might additionally 
contribute to the hemostatic changes (8, 9). Interestingly, in 
both ET and PV, the slightly elevated white blood cell count 
at the time of the hematological diagnosis was not decreased 
at the time of the MI, when the white blood cell count was 
even higher despite the hematological treatment. From a car-
diological point of view, the importance of the elevated white 
blood cell count and the relationship between the baseline 
white blood cell count and the degree of coronary artery dis-
ease in patients with acute coronary syndromes has already 
been established (40, 41). The relevant literature on MPNs re-
veals that the quantitative role of the white blood cell count in 
thrombotic complications and its predictive role in thrombo-
sis stratification are still under consideration, and there have 
been few reports of the qualitative role of leukocytes, in which 
platelet–leukocyte interactions might be indicative of platelet 
activation in MPN (42–45).
Study limitations
A limitation of our study is its retrospective design.
Conclusions 
It should be concluded that early diagnosis of MPNs is es-
sential for the prognosis and subsequent therapy-related throm-
bosis risk stratification in ET/PV patients, with emphasis on MI 
as a major complication. The result of the present study could 
suggest that most of MI developed within 12 months following 
the diagnosis of ET/PV, with evident implications for the neces-
sity of early detection and personalized management of vascular 
risk factors in this group of patients. Furthermore, better theo-
retic understanding of platelet activation and role of leukocytes 
in MPN-related thrombosis could open new perspectives in 
thrombosis prediction and prevention.
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